Interestingly, tau protein was the target of previously published works on active peptide vaccines for the treatment of Alzheimer disease, targeting either phosphorylated or non-phosphorylated tau protein, which also entered clinical studies [48]. The gene discussed is MAPT; the disease is Alzheimer disease.